You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
McKinsey
Express Scripts
Boehringer Ingelheim
Colorcon

Last Updated: February 21, 2020

DrugPatentWatch Database Preview

Patent: 10,279,014

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,279,014
Title:Gene editing methods and compositions for eliminating risk of JC virus activation and PML (progressive multifocal leukoencephalopathy) during immunosuppressive therapy
Abstract: A method of eliminating the risk of JCV activation in a subject undergoing immunosuppressive therapy, by administering an effective amount of a gene editing composition directed toward at least one target sequence in the JCV genome, cleaving the target sequence in the JCV genome, disrupting the JCV genome, eliminating the JCV infection, eliminating the risk of JCV activation, and treating the subject with an immunosuppressive therapy. A pharmaceutical composition including at least one isolated nucleic acid sequence encoding a CRISPR-associated endonuclease and at least one gRNA having a spacer sequence complementary to a target sequence in a JCV DNA, the isolated nucleic acid sequences being included in at least one expression vector. Pharmaceutical compositions including at least one isolated nucleic acid sequence encoding at least one TALEN, at least one ZFN, and gene editing composition of C2c1, C2c3, TevCas9, Archaea Cas9, CasY.1-CasY.6, CasX, or argonaute protein, which target at least one nucleotide sequence of the JCV genome.
Inventor(s): Khalili; Kamel (Bala Cynwyd, PA), Malcolm; Thomas (Bedminster, NJ), Kohn; Kenneth I. (West Bloomfield, MI)
Assignee: Excision BioTherapeutics, Inc. (Bedminster, unknown) Temple University of the Commonwealth System of Higher Education (Philadelphia, unknown)
Application Number:15/864,309
Patent Claims:see list of patent claims

Details for Patent 10,279,014

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Excision BioTherapeutics, Inc. (Bedminster, unknown) Temple University of the Commonwealth System of Higher Education (Philadelphia, unknown) 2039-05-17 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Excision BioTherapeutics, Inc. (Bedminster, unknown) Temple University of the Commonwealth System of Higher Education (Philadelphia, unknown) 2039-05-17 RX search
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24   Start Trial Excision BioTherapeutics, Inc. (Bedminster, unknown) Temple University of the Commonwealth System of Higher Education (Philadelphia, unknown) 2039-05-17 RX Orphan search
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23   Start Trial Excision BioTherapeutics, Inc. (Bedminster, unknown) Temple University of the Commonwealth System of Higher Education (Philadelphia, unknown) 2039-05-17 RX search
Bristol Myers Squibb NULOJIX belatacept INJECTABLE; INJECTION 125288 001 2011-06-15   Start Trial Excision BioTherapeutics, Inc. (Bedminster, unknown) Temple University of the Commonwealth System of Higher Education (Philadelphia, unknown) 2039-05-17 RX search
Seattle Genetics ADCETRIS brentuximab vedotin INJECTABLE; INJECTION 125388 001 2011-08-19   Start Trial Excision BioTherapeutics, Inc. (Bedminster, unknown) Temple University of the Commonwealth System of Higher Education (Philadelphia, unknown) 2039-05-17 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Medtronic
Johnson and Johnson
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.